|Bid||72.210 x 100|
|Ask||72.320 x 300|
|Day's Range||70.790 - 73.620|
|52 Week Range||31.380 - 80.110|
|PE Ratio (TTM)||-14.93|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Alnylam Pharmaceuticals, Inc. (ALNY) shares jump a little above 16% in the last trading session.
Alnylam stock rocketed to a seven-month high Monday after a Phase 3 trial from rival Ionis de-risked a key Alnylam drug while indicating serious safety questions for Ionis' drug.
The string of severe adverse events with Ionis' inotersen program puts competitor Alnylam in a more favorable position.